Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline.

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.

Founded in 2009 and acquired by Gilead Sciences in 2017, Kite has been a pioneer in cell therapy research and leader in the immuno-oncology space.

Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated.

Aug 28, 2017 · FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash.

At Kite, a Gilead Company, our singular focus is achieving cures with cell therapy. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit....

Dec 30, 2024 · KITE-197 is under clinical development by Kite Pharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Kite’s impact has rapidly scaled from being able to treat hundreds of patients per year to now having treated 19,500 since Kite’s CAR T therapies have been approved. Given that each cell therapy is uniquely designed for each patient, manufacturing is central to how Kite delivers their therapies, “We’re the only company that has end-to-

Oct 3, 2017 · Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care.

Learn about Kite’s mission to change the way cancer is treated with cell therapy – the use of genetically modified immune cells programmed to target tumors.